Skip to main content

Table 3 Radiographic changes from baseline after 2 years of treatment

From: Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study

  MTX (n = 37) TwHF (n = 34) MTX + TwHF (n = 38) P
JE at baseline (range 0–280)     
mean (SD) 16.76 (22.56) 20.83 (29.02) 14.92 (21.26)  
median (IQR) 7.25 (2.00, 25.00) 7.00 (2.75, 27.00) 5.00 (2.75,15.50) 0.589
JSN at baseline (range 0–168)     
mean (SD) 11.92 (15.35) 13.05 (16.18) 12.34 (16.06)  
median (IQR) 6.25 (0, 17.50) 3.00 (0.75, 30.75) 5.00 (1.25, 21.00) 0.957
TSS at baseline     
mean (SD) 28.68 (35.54) 33.88 (42.97) 26.99 (35.81)  
median (IQR) 14.75 (2.75, 42.13) 15.00 (5.00, 47.00) 14.5 (5.00, 35.25) 0.738
Estimated annual radiographic progression at baseline     
mean (SD) 20.96 (78.12) 13.02 (15.07) 10.84 (15.90)  
median (IQR) 5.74 (1.88, 10.21) 6.25 (3.51, 20.17) 5.61 (2.25, 10.37) 0.635
mTSS at 2 years     
mean (SD) 31.94 (37.54) 36.57 (44.04) 30.21 (35.99)  
median (IQR) 15.25 (3.94, 42.00) 18.00 (5.50, 51.67) 15.71 (7.41, 38.81) 0.826
ΔmJE     
mean (SD) 1.59 (4.43) 1.33 (2.03) 1.44 (3.22)  
median (IQR) 0 (0, 1.21) 0.75 (0, 2.32) 0.77 (0, 1.50) 0.939
ΔmJSN     
mean (SD) 1.67 (3.32) 1.31 (2.41) 1.78 (3.24)  
median (IQR) 0 ( 0, 1.13) 0 (0, 1. 52) 0 (0, 2.19) 0.781
ΔmTSS     
mean (SD) 3.24 (6.95) 2.70 (3.70) 3.22 (5.66)  
median (IQR) 0.61 (0,4.18) 1.00 (0,4.14) 1.04 (0,3.62) 0.862
ΔmTSS <0.5 17 (45.95%) 12 (35.29%) 13 (34.21%) 0.520
ΔmTSS ≤SDD (5.24) 31 (83.78%) 27 (79.41%) 31 (81.58%) 0.893
ΔmJE ≤SDD (3.37) 32 (86.49%) 31 (91.18%) 35 (92.11%) 0.691
ΔmJSN ≤SDD (2.85) 30 (81.08%) 27 (79.41%) 31 (81.58%) 0.955
  1. MTX methotrexate, TwHF Tripterygium wilfordii Hook F, JE joint erosion, JSNjoint space narrowing, TSS total Sharp score, mTSS modified total Sharp score, SSD smallest detectable difference
  2. Data are presented as mean (standard deviation, SD) and median (interquartile range, IQR)
  3. The p values were calculated using analysis of variance for baseline scores, while comparison for estimated progression and scores at year 2 was performed using analysis of covariance with baseline score as a covariate. Comparison of the change in score <0.5 or equal to or less than the smallest detectable difference was conducted using the χ2 test
  4. Estimated annual radiological progression at baseline was defined as the baseline mTSS score divided by disease duration for each patient